Stress echocardiography (SE) helps provide a dynamic observation of myocardial structure and function change under physiological (exercise) or pharmacological conditions. The most frequent clinical application is the assessment of known or suspected ischemic heart disease. It is also establishing a role in evaluating various non-ischemic heart diseases. For example, in the past few decades, SE has become an established method for the assessment of a wide range of challenging clinical conditions, including systolic or diastolic heart failure, non-ischemic cardiomyopathy, valvular heart disease, pulmonary hypertension (PH), congenital heart disease (CHD).
Even though the application of SE has broadened, there are still concerns that need to be addressed. For example, more evidence should be collected for its proper application in various clinical scenarios such as verifying diagnostic cut-off values in a larger sample size. There are also new parameters emerging, including contractile reserve and diastolic reserve, that may enhance the application of SE in various pathophysiological conditions. Therefore, it is also worthwhile to further explore whether SE could be used as potential tool for the early diagnosis, prognosis evaluation, and risk stratification in new scenarios, such as onco-cardiology. With new advancement in the SE techniques in recent years, an inclusive analysis centering on its clinical application will be of great value.
In this Research Topic, we would like to discuss the state-of-the-art advances of SE techniques, and its applications in various heart diseases to gain a bigger picture of its overall development.
We welcome submissions on the following topics, but are not limited to:
- Research progress review of SE in heart disease, especially in oncocardiology
- New techniques and parameters of SE used in ischemic heart disease, cutoff values of new parameters for diagnosis
- Application of SE in heart failure with depressed LV systolic function and nonischemic cardiomyopathy, and novel parameters applied for prognosis evaluation
- The role of SE in the management of valvular heart disease, especially in transcatheter therapy decision making and prognosis
- Novel parameters and cutoff values of SE for early diagnosis of latent pulmonary hypertension and prognosis assessment
- Early diagnosis of myocardial dysfunction by SE in oncocardiology
Stress echocardiography (SE) helps provide a dynamic observation of myocardial structure and function change under physiological (exercise) or pharmacological conditions. The most frequent clinical application is the assessment of known or suspected ischemic heart disease. It is also establishing a role in evaluating various non-ischemic heart diseases. For example, in the past few decades, SE has become an established method for the assessment of a wide range of challenging clinical conditions, including systolic or diastolic heart failure, non-ischemic cardiomyopathy, valvular heart disease, pulmonary hypertension (PH), congenital heart disease (CHD).
Even though the application of SE has broadened, there are still concerns that need to be addressed. For example, more evidence should be collected for its proper application in various clinical scenarios such as verifying diagnostic cut-off values in a larger sample size. There are also new parameters emerging, including contractile reserve and diastolic reserve, that may enhance the application of SE in various pathophysiological conditions. Therefore, it is also worthwhile to further explore whether SE could be used as potential tool for the early diagnosis, prognosis evaluation, and risk stratification in new scenarios, such as onco-cardiology. With new advancement in the SE techniques in recent years, an inclusive analysis centering on its clinical application will be of great value.
In this Research Topic, we would like to discuss the state-of-the-art advances of SE techniques, and its applications in various heart diseases to gain a bigger picture of its overall development.
We welcome submissions on the following topics, but are not limited to:
- Research progress review of SE in heart disease, especially in oncocardiology
- New techniques and parameters of SE used in ischemic heart disease, cutoff values of new parameters for diagnosis
- Application of SE in heart failure with depressed LV systolic function and nonischemic cardiomyopathy, and novel parameters applied for prognosis evaluation
- The role of SE in the management of valvular heart disease, especially in transcatheter therapy decision making and prognosis
- Novel parameters and cutoff values of SE for early diagnosis of latent pulmonary hypertension and prognosis assessment
- Early diagnosis of myocardial dysfunction by SE in oncocardiology
